United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - captopril (unii: 9g64rsx1xd) (captopril - unii:9g64rsx1xd) - captopril 12.5 mg - hypertension: captopril tablets us?are indicated for the teatment of hypertension. tn using captopril, conslderallon should be gtven to the risk of neutropenia!agranutocytosls (seewarnings). captoprll maybe used as initial therapy for patientswilh normal renal function, in whomthe rlskls relatively low. in patients with impaired renal function, particularly those wfth collagen vascular olseas6, captopril should be resened for,hypertenslves who have either developed unacceptable side effecls on otherdrugs, orhave failed to responq satislactorily 10drug combinations. captopril is effective alone and in combination with other antihypertensive agents, ~peclally thiazide-type diuretics. the blood pressure lowering effecls of captoprif and thlazldes are approximalaly a

Malta - English - Medicines Authority

bioton sa ul. staroscinska 5, 02-516, warsaw, poland - insulin human, rdna - solution for injection - insulin human (rdna) 100 iu/ml - drugs used in diabetes

Malta - English - Medicines Authority

bioton sa ul. staroscinska 5, 02-516, warsaw, poland - insulin human, rdna - solution for injection - insulin human (rdna) 100 iu/ml - drugs used in diabetes

Australia - English - Department of Health (Therapeutic Goods Administration)

maxx pharma pty ltd - insulin glargine, quantity: 100 u/ml - injection, solution - excipient ingredients: sodium hydroxide; glycerol; water for injections; hydrochloric acid; metacresol; zinc chloride - insulin glargine is an insulin analogue indicated for once-daily subcutaneous administration in the treatment of type 1 diabetes mellitus in adults and children and type 2 diabetes mellitus in adults who require insulin for the control of hyperglycaemia.

Israel - English - Ministry of Health

sanofi israel ltd - insulin glargine; lixisenatide - solution for injection - lixisenatide 33 mcg / 1 ml; insulin glargine 100 units / 1 ml - insulin glargine - suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without sodium-glucose co-transporter-2 (sglt-2) inhibitors

Israel - English - Ministry of Health

sanofi israel ltd - insulin glargine; lixisenatide - solution for injection - lixisenatide 50 mcg / 1 ml; insulin glargine 100 units / 1 ml - insulin glargine - suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without sodium-glucose co-transporter-2 (sglt-2) inhibitors.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - insulin glargine 100 iu/ml equivalent to 3.6378mg/ml - solution for injection - 100 iu/ml - active: insulin glargine 100 iu/ml equivalent to 3.6378mg/ml excipient: glycerol hydrochloric acid metacresol polysorbate 20 sodium hydroxide water for injection zinc chloride - optisulin/optisulin solostar is an insulin analogue indicated for once-daily subcutaneous administration in the treatment of type 1 or type 2 diabetes mellitus patients who require insulin for the control of hyperglycaemia.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - insulin glargine 100 iu/ml equivalent to 3.6378mg/ml - solution for injection - 100 iu/ml - active: insulin glargine 100 iu/ml equivalent to 3.6378mg/ml excipient: glycerol hydrochloric acid metacresol sodium hydroxide water for injection zinc chloride - optisulin/optisulin solostar is an insulin analogue indicated for once-daily subcutaneous administration in the treatment of type 1 or type 2 diabetes mellitus patients who require insulin for the control of hyperglycaemia.

European Union - English - EMA (European Medicines Agency)

sanofi winthrop industrie - insulin glargine, lixisenatide - diabetes mellitus, type 2 - drugs used in diabetes - suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without sglt-2 inhibitors.,

United States - English - NLM (National Library of Medicine)

pfizer inc. - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - kit - 1 mg - exubera is indicated for the treatment of adult patients with diabetes mellitus for the control of hyperglycemia. exubera has an onset of action similar to rapid-acting insulin analogs and has a duration of glucose-lowering activity comparable to subcutaneously administered regular human insulin. in patients with type 1 diabetes, exubera should be used in regimens that include a longer-acting insulin. in patients with type 2 diabetes, exubera can be used as monotherapy or in combination with oral agents or longer-acting insulins. exubera is contraindicated in patients hypersensitive to exubera or one of its excipients. exubera is contraindicated in patients who smoke or who have discontinued smoking less than 6 months prior to starting exubera therapy. if a patient starts or resumes smoking, exubera must be discontinued immediately due to the increased risk of hypoglycemia, and an alternative treatment must be utilized (see clinical pharmacology, special populations, smoking). the safety and efficacy of exube